?. Comorbidities and . Any, Asthma (n=20,518) COPD (n=17,081) Other chronic lung disease (n=17,853) Heart disease (n=18,419) Renal disease (n=19,860) Liver disease (n=12,264) Cerebrovascular disease (n=9,803) Neurological disease (n=13,598) Diabetes (n=24,764) Immunosuppression (n=25, 9·7) 1,012 (3·5)4·8) of the final report. Each author acts as the guarantor of data from their individual study centre, pp.11479471-134

, T and PRM act as overall guarantors for the pooled analysis and the report


M. De, L. Aguiar-oliveira, M. A. Masri, and R. Amin,

C. Orcal, J. Bantar, . Bao, M. Mazen, A. Barhoush et al.,

B. Khavidaki and . Du,

J. Gerrard, S. Gormley, S. Götberg, M. Hoffmann, and B. Honarvar,

H. Leibovici, X. Li, R. Li, . Libster, P. Tze et al.,

A. Somer, M. Thiago, P. Souza, . Tabarsi, B. Chandrabhanu et al.,

S. Jonathan and . Nguyen-van-tam, JSN-V-T) undertook ad hoc paid consultancy and lecturing for several influenza vaccine manufacturers, 2007.

G. Sanofi-pasteur, . Gsk-), and A. Baxter, Solvay, Novartis) and manufacturers of neuraminidase inhibitors (F. Hoffmann-La Roche: oseltamivir (Tamiflu®) and GSK: zanamivir (Relenza®)) He is a former employee of both SmithKline Beecham plc (now part of GSK), Roche Products Ltd. (UK), and Sanofi-Pasteur MSD, all prior to 2005) He has no outstanding interests related to shares, share options or accrued pension rights in any of these companies. He is in receipt of current or recent research funding, related to influenza vaccination from GSK and Astra-Zeneca and non-financial support (travel) from Baxter AG His brother became an employee of GSK

B. Donner, S. Bader-weder, R. Schwarz, M. Peng, J. Smith et al., Safety profile of oseltamivir during the 2009 influenza pandemic, Pharmacoepidemiology and Drug Safety, vol.9, issue.10, pp.532-575, 2011.
DOI : 10.1016/S1473-3099(09)70233-6

C. Atkins, A. Patel, T. Taylor, and . Jr, Estimating Effect of Antiviral Drug Use during Pandemic (H1N1) 2009 Outbreak, United States, Emerging Infectious Diseases, vol.17, issue.9, pp.1591-1599, 2011.
DOI : 10.3201/eid1709.110295

R. Chemaly, S. Ghosh, and G. Bodey, Respiratory Viral Infections in Adults With Hematologic Malignancies and Human Stem Cell Transplantation Recipients, Medicine, vol.85, issue.5, pp.278-87, 2006.
DOI : 10.1097/01.md.0000232560.22098.4e

R. Chemaly, H. Torres, and E. Aguilera, Neuraminidase Inhibitors Improve Outcome of Patients with Leukemia and Influenza: An Observational Study, Clinical Infectious Diseases, vol.1, issue.2, pp.964-971, 2007.
DOI : 10.4065/74.12.1266

W. Hanshaoworakul, J. Simmerman, and U. Narueponjirakul, Severe Human Influenza Infections in Thailand: Oseltamivir Treatment and Risk Factors for Fatal Outcome, PLoS ONE, vol.4, issue.6, 2009.
DOI : 10.1371/journal.pone.0006051.t003

K. Hassan, A. Mcgeer, and K. Green, Antiviral therapy improves outcomes of influenza infections in patients requiring admission to intensive care. 49th Interscience Conference on, Antimicrobial Agents and Chemotherapy, pp.12-15, 2009.

N. Lee, K. Choi, and P. Chan, Outcomes of adults hospitalised with severe influenza, Thorax, vol.65, issue.6, pp.510-515, 2010.
DOI : 10.1136/thx.2009.130799

A. Mcgeer, K. Green, and A. Plevneshi, Antiviral Therapy and Outcomes of Influenza Requiring Hospitalization in Ontario, Canada, Clinical Infectious Diseases, vol.43, issue.4, pp.1568-75, 2007.
DOI : 10.1086/505868

W. Nichols, K. Guthrie, L. Corey, and M. Boeckh, Influenza Infections after Hematopoietic Stem Cell Transplantation: Risk Factors, Mortality, and the Effect of Antiviral Therapy, Clinical Infectious Diseases, vol.52, issue.RR-8, pp.1300-1306, 2004.
DOI : 10.1136/bmj.326.7401.1235

W. Adisasmito, P. Chan, and N. Lee, Effectiveness of Antiviral Treatment in Human Influenza A(H5N1) Infections: Analysis of a Global Patient Registry, The Journal of Infectious Diseases, vol.202, issue.8, pp.1154-60, 2010.
DOI : 10.1086/656316

P. Chan, N. Lee, and M. Zaman, Characteristics of pregnant Japanese women who required hospitalization for treatment of pandemic (H1N1) 2009--low mortality rate may be due to early antiviral use 232- 3. 13. Sugaya N. Widespread use of neuraminidase inhibitors in Japan Very low pandemic influenza A (H1N1) 2009 mortality associated with early neuraminidase inhibitor treatment in Japan: Analysis of 1000 hospitalized children, Determinants of Antiviral Effectiveness in Influenza Virus A Subtype H5N1, pp.1359-66, 2011.

J. Hsu, N. Santesso, and R. Mustafa, Antivirals for Treatment of Influenza, Annals of Internal Medicine, vol.156, issue.7, pp.512-536, 2012.
DOI : 10.7326/0003-4819-156-7-201204030-00411

URL : http://annals.org/data/journals/aim/22438/0000605-201204030-00008.pdf

S. Muthuri, P. Myles, S. Venkatesan, J. Leonardi-bee, and J. Nguyen-van-tam, Impact of Neuraminidase Inhibitor Treatment on Outcomes of Public Health Importance During the 2009-2010 Influenza A(H1N1) Pandemic: A Systematic Review and Meta-Analysis in Hospitalized Patients, Journal of Infectious Diseases, vol.67, issue.8, pp.553-63, 2013.
DOI : 10.1136/thoraxjnl-2011-200266

R. Riley, P. Lambert, and G. Abo-zaid, Meta-analysis of individual participant data: rationale, conduct, and reporting, BMJ, vol.340, issue.feb05 1, 2010.
DOI : 10.1136/bmj.c221

URL : http://www.bmj.com/content/bmj/340/bmj.c221.full.pdf

V. Harder, E. Stuart, and J. Anthony, Propensity score techniques and the assessment of measured covariate balance to test causal associations in psychological research., Psychological Methods, vol.15, issue.3, pp.73-84, 2004.
DOI : 10.1037/a0019623

P. Myles, J. Leonardi-bee, J. Van-tam, S. Muthuri, and S. Venkatesan, A systematic review of the impact of neuraminidase inhibitor antiviral use on outcomes of public health importance during theswine) influenza A/H1N1v pandemic Influenza antiviral medications: summary for clinicians, Centers for Disease Control and Prevention, vol.10, issue.22, 2009.

G. Chowell, C. Viboud, and L. Simonsen, Impact of antiviral treatment and hospital admission delay on risk of death associated with 2009 A/H1N1 pandemic influenza in Mexico (H1N1) Mortality during the 2009-2010 H1N1 Pandemic: An Ecological Study, al. Risk factors for severe outcomes following 2009 influenza A (H1N1) infection: a global pooled analysis, pp.481-485, 2009.

, PLoS Med, vol.8, issue.7, pp.1001053-1001080, 2011.

W. Jessica, Y. , K. Heath, I. Dennis, K. M. et al., Case fatality risk of influenza A(H1N1pdm09): a systematic review, Epidemiology, vol.24, issue.6, pp.830-871, 2013.

C. Li, L. Wang, and H. Eng, Correlation of Pandemic (H1N1) 2009 Viral Load with Disease Severity and Prolonged Viral Shedding in Children, Emerging Infectious Diseases, vol.16, issue.8, pp.1265-72, 2010.
DOI : 10.3201/eid1608.091918

D. Kimberlin, E. Acosta, and M. Prichard, Oseltamivir Pharmacokinetics, Dosing, and Resistance Among Children Aged <2 Years With Influenza, The Journal of Infectious Diseases, vol.201, issue.14, pp.709-729, 2013.
DOI : 10.1086/652498

L. Signorello, J. Mclaughlin, L. Lipworth, S. Friis, H. Sorensen et al., Confounding by Indication in Epidemiologic Studies of Commonly Used Analgesics, American Journal of Therapeutics, vol.9, issue.3
DOI : 10.1097/00045391-200205000-00005

S. Sun, G. Zhao, and W. Xiao, Age-related sensitivity and pathological differences in infections by 2009 pandemic influenza A (H1N1) virus, Virology Journal, vol.8, issue.1, pp.199-205, 2002.
DOI : 10.1186/1743-422X-8-52

J. Louie, S. Yang, M. Samuel, T. Uyeki, and R. Schechter, Neuraminidase Inhibitors for Critically Ill Children With Influenza, PEDIATRICS, vol.132, issue.6, pp.1539-1584, 2013.
DOI : 10.1542/peds.2013-2149

D. Hui and N. Lee, Adjunctive therapies and immunomodulating agents for severe influenza, Influenza and Other Respiratory Viruses, vol.105, issue.Suppl. 2, pp.52-61, 2013.
DOI : 10.1073/pnas.0711942105

P. Myles, J. Nguyen-van-tam, and M. Semple, Differences between asthmatics and nonasthmatics hospitalised with influenza A infection, European Respiratory Journal, vol.41, issue.4, pp.824-855, 2013.
DOI : 10.1183/09031936.00015512